A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.
Haura
Eric B
EB
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA. eric.haura@moffitt.org
Ricart
Alejandro D
AD
Larson
Timothy G
TG
Stella
Philip J
PJ
Bazhenova
Lyudmila
L
Miller
Vincent A
VA
Cohen
Roger B
RB
Eisenberg
Peter D
PD
Selaru
Paulina
P
Wilner
Keith D
KD
Gadgeel
Shirish M
SM